A story in the Sept. 15, 2005, issue of BioWorld Today should have said MedImmune Inc. is paying an up-front fee, milestones and royalties to GlaxoSmithKline plc in a licensing deal for anti-staphylococcal monoclonal antibodies. Also, MedImmune has given no exact guidance on the amount of FluMist doses that will be available for this year's flu season.

Editor's Note: The correction will be made in BioWorld online.

No Comments